
|Videos|August 26, 2021
Part 2: Practical Considerations For Venetoclax in AML
Expert continues discussion on important considerations for the optimal use if venetoclax in patients with AML, such as CYP3A4 and p-glycoprotein drug interactions.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
2
Antibody-Drug Conjugates and HER2 Guidelines Are Reshaping Breast Cancer Treatment
3
Workforce Preparation for Fall Immunization Season Starts Now
4
Clinical Forum Events Highlight the Evolving Landscape of Obesity Management
5







































































































